Related Experiment Videos
[p53 gene point mutation in human colorectal carcinoma]
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]
|September 1, 1995
Summary
Point mutations in p53 exon 7 were identified in colorectal cancer, correlating with aggressive disease. This finding suggests p53 exon 7 mutations may serve as a prognostic marker for colorectal carcinomas.
Area of Science:
- Molecular biology
- Oncology
- Genetics
Context:
- Colorectal cancer (CRC) is a significant global health concern.
- Understanding the molecular basis of CRC progression is crucial for improved patient outcomes.
- The p53 tumor suppressor gene plays a critical role in cellular response to DNA damage.
Purpose:
- To investigate the presence and significance of p53 exon 7 mutations in colorectal carcinomas.
- To evaluate the association of these mutations with clinicopathological features and disease stage.
Summary:
- Two modified assay systems, PCR-SSCP and PCR-direct sequencing, were employed to analyze p53 exon 7 in 22 colorectal carcinomas and 1 metastatic lymph node.
- Point mutations were detected in 27.2% of colorectal carcinomas and the metastatic lymph node, specifically in codons 245, 251, 259, and 260.
- Mutations included G:C to A:T transitions, base insertions, and deletions, with codon 245 being a common site for G:C to A:T transitions.
Impact:
- p53 exon 7 point mutations were significantly associated with poorly differentiated primary carcinomas (P = 0.0178).
- A higher mutation rate was observed in Duke's stage C compared to stages A and B (P = 0.0361).
- These findings suggest that p53 exon 7 mutations may identify a subgroup of colorectal cancer patients with more aggressive disease, potentially serving as a novel prognostic marker.